A patient with a severe bloodstream infection caused by Escherichia coli resistant to multiple classes of antibiotics received an experimental treatment combining bacteriophages with CRISPR-Cas gene-editing machinery.
The phages were engineered to infect the target E. coli strain and deliver a CRISPR system programmed to cut essential bacterial genes, disabling the pathogen's ability to survive and replicate.
After standard antibiotics failed to control the infection, clinicians administered the CRISPR-armed phage preparation under a compassionate-use protocol.
Follow-up testing showed the resistant E. coli was cleared from the patient's blood, and the patient's condition improved without evidence of adverse effects from the engineered phages.
Researchers caution that this is a single case report and not a controlled clinical trial, so broader efficacy and safety remain unknown.
The approach aims to overcome a key limitation of traditional phage therapy: bacteria can evolve resistance to natural phages, but CRISPR targeting of essential genes may reduce that risk.
Further studies are needed to determine optimal dosing, potential immune responses to the phage components, and whether the strategy works across diverse bacterial strains and infection sites.
If validated in larger trials, CRISPR-enhanced phages could expand the therapeutic options for infections that no longer respond to any available antibiotics.
CRISPR-armed phages help treat severe superbug infection
This is an independent summary. The complete reporting, supporting context and any primary documents remain with New Scientist.